Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.

Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, Iwama A.

Blood. 2012 Aug 2;120(5):1107-17. doi: 10.1182/blood-2011-11-394932. Epub 2012 Jun 7.

2.

Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.

Fiskus W, Pranpat M, Balasis M, Herger B, Rao R, Chinnaiyan A, Atadja P, Bhalla K.

Mol Cancer Ther. 2006 Dec;5(12):3096-104.

3.

Polycomb repressive complex 2 is required for MLL-AF9 leukemia.

Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5028-33. doi: 10.1073/pnas.1202258109. Epub 2012 Mar 6.

4.

The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.

Thiel AT, Feng Z, Pant DK, Chodosh LA, Hua X.

Haematologica. 2013 Jun;98(6):918-27. doi: 10.3324/haematol.2012.074195. Epub 2013 Jan 24.

5.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, Ustun C, Rao R, Fernandez P, Chen J, Balusu R, Koul S, Atadja P, Marquez VE, Bhalla KN.

Blood. 2009 Sep 24;114(13):2733-43. doi: 10.1182/blood-2009-03-213496. Epub 2009 Jul 28.

6.

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.

Zhou J, Bi C, Cheong LL, Mahara S, Liu SC, Tay KG, Koh TL, Yu Q, Chng WJ.

Blood. 2011 Sep 8;118(10):2830-9. doi: 10.1182/blood-2010-07-294827. Epub 2011 Jul 6.

7.

Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.

Nishioka C, Ikezoe T, Yang J, Yokoyama A.

PLoS One. 2015 May 8;10(5):e0125017. doi: 10.1371/journal.pone.0125017. eCollection 2015.

8.

EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.

Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, Jin H, Choy KW, Yu J, To KF, Wong N, Huang TH, Sung JJ.

Cancer Res. 2011 Jun 1;71(11):4028-39. doi: 10.1158/0008-5472.CAN-10-3342. Epub 2011 Apr 21.

9.

Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.

Ueda K, Yoshimi A, Kagoya Y, Nishikawa S, Marquez VE, Nakagawa M, Kurokawa M.

Cancer Sci. 2014 May;105(5):512-9. doi: 10.1111/cas.12386. Epub 2014 Mar 30.

10.

A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.

Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, Boucher G, Chagnon P, Drouin S, Lambert R, Rondeau C, Bilodeau A, Lavallée S, Sauvageau M, Hébert J, Sauvageau G.

Genes Dev. 2012 Apr 1;26(7):651-6. doi: 10.1101/gad.186411.111. Epub 2012 Mar 19.

11.

Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.

Karanikolas BD, Figueiredo ML, Wu L.

Mol Cancer Res. 2009 Sep;7(9):1456-65. doi: 10.1158/1541-7786.MCR-09-0121. Epub 2009 Sep 1.

12.

CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells.

Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, Yang CC, Yang JY, Lin CY, Lai CC, Hung MC.

Nat Cell Biol. 2011 Jan;13(1):87-94. doi: 10.1038/ncb2139. Epub 2010 Dec 5.

13.

EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.

Blood. 2012 Jun 14;119(24):5838-49. doi: 10.1182/blood-2011-11-393827. Epub 2012 May 2.

14.

Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.

Danis E, Yamauchi T, Echanique K, Haladyna J, Kalkur R, Riedel S, Zhu N, Xie H, Bernt KM, Orkin SH, Armstrong SA, Neff T.

Exp Hematol. 2015 Nov;43(11):930-935.e6. doi: 10.1016/j.exphem.2015.06.005. Epub 2015 Jun 26.

15.

Targeting the enhancer of zeste homologue 2 in medulloblastoma.

Alimova I, Venkataraman S, Harris P, Marquez VE, Northcott PA, Dubuc A, Taylor MD, Foreman NK, Vibhakar R.

Int J Cancer. 2012 Oct 15;131(8):1800-9. doi: 10.1002/ijc.27455. Epub 2012 Jul 30.

16.

Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.

Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV.

Cell Cycle. 2006 Aug;5(16):1886-901. Epub 2006 Aug 15.

PMID:
16963837
17.

EZH2 methyltransferase and H3K27 methylation in breast cancer.

Yoo KH, Hennighausen L.

Int J Biol Sci. 2012;8(1):59-65. Epub 2011 Nov 18. Review.

18.

Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells.

Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T, Shinga J, Koseki H, Iwama A.

Blood. 2011 Dec 15;118(25):6553-61. doi: 10.1182/blood-2011-03-340554. Epub 2011 Oct 31. Erratum in: Blood. 2012 Jul 26;120(4):924.

19.

The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.

Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, Komiya S.

Oncol Rep. 2010 Mar;23(3):677-84.

PMID:
20127006
20.

Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.

Grimaldi G, Christian M, Steel JH, Henriet P, Poutanen M, Brosens JJ.

Mol Endocrinol. 2011 Nov;25(11):1892-903. doi: 10.1210/me.2011-1139. Epub 2011 Sep 8.

Supplemental Content

Support Center